Calcium Folinate and Sodium Chloride Injection

This product is a formyl derivative of tetrahydrofolate, mainly used for the rescue of high-dose methotrexate and other folic acid antagonists. It inhibits the synthesis of DNZ. After entering the body, this product is converted into tetrahydrofolate by tetrahydrofolate reductase, which can effectively counteract the toxic reaction caused by methotrexate, but has no obvious effect on the existing methotrexate neurotoxicity.

Main ingredient: Calcium folinate. Chemical name: N-[4-[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pterydinyl)methyl]amino]benzoyl-L-glutamic acid calcium salt pentahydrate.

This product is a colorless clear liquid.

1. Used as an antidote for folic acid antagonists (such as methotrexate, pyrimethamine or trimethoprim, etc.). 2. Used to prevent and treat severe toxic effects caused by excessive or high-dose treatment with methotrexate. 3. Megaloblastic anemia caused by folic acid deficiency. 4. Used in combination with 5-fluorouracil to treat advanced colorectal cancer.

1. Calcium folinate "rescue" therapy after high-dose methotrexate treatment: The dose of calcium folinate is determined according to the drug concentration of methylpterin. Generally, 24 hours after intravenous injection of methotrexate, the dose is 10 mg/㎡ based on body surface area, once every 6 hours, for a total of 10 times. Do not inject this product intravenously. Guidelines for the use of calcium folinate: Clinical situation Laboratory examination Calcium folinate dose and course of treatment Methotrexate routine elimination 24 hours after administration, plasma methotrexate levels are about 10 μmol, about 1 μmol after 48 hours, and less than 0.2 μmol after 72 hours. Within 60 hours, 15 mg is injected intramuscularly or intravenously, once every 6 hours (starting 24 hours after the use of methotrexate, for a total of 10 doses). Late delayed elimination of methotrexate 72 hours after administration, the plasma methotrexate level is greater than 0.20.2 μmol, and is still greater than 0.05 μmol at 96 hours of medication. Continue to give 15 mg intravenously or intravenously every 6 hours until the methotrexate level is less than 0.05 μmol. Early delayed elimination of methotrexate and/or acute kidney injury Plasma methotrexate level is greater than or equal to 50 μmol 24 hours after administration, or greater than or equal to 5 μmol 48 hours after administration, or after the use of methotrexate, the serum creatinine increases by more than 100% in 24 hours. Give 150 mg intravenously every 3 hours until the methotrexate level is less than 1 μmol, then give 15 mg IV every 3 hours until the methotrexate level is less than 0.05 μmol. 2 When methotrexate is not eliminated smoothly or is accidentally used in overdose: When methotrexate is accidentally used in overdose, calcium folinate should be used as soon as possible for emergency treatment; when excretion is delayed, calcium folinate should also be used within 24 hours of methotrexate use. Generally, 10 mg of calcium folinate is injected intramuscularly or intravenously every 6 hours until the blood methotrexate level is lower than 10-8M (0.01 μmol). When digestive system reactions (such as nausea and vomiting) occur, calcium folinate can be administered parenterally, but this product cannot be injected intravenously. Serum creatinine and methotrexate levels are measured every 24 hours. If the 24-hour blood creatinine increases by more than 50% or the 24-hour methotrexate exceeds 9×10-7M, the calcium folinate dose is increased to 100 mg/㎡, once every 3 hours, until the methotrexate level is lower than 10-8M. 3 For megaloblastic anemia caused by folic acid deficiency, generally 1 mg per day, there is no evidence to prove that increasing the dose will increase the efficacy. 4 Colorectal cancer: used in combination with 5-Fu to increase radiation dose, 20-500 mg/㎡ each time, intravenous drip, once a day, for 5 consecutive days.

Rarely, other allergic reactions such as rash, urticaria or asthma may occur.

Megaloblastic anemia caused by pernicious anemia or vitamin B12 deficiency.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

The use of this product in large doses together with barbiturates, primidone or phenytoin sodium may affect its anti-epileptic effect.

Store in a closed, cool and dark place.

100ml: 0.1g calcium folinate and 0.9g sodium chloride

24 months

Dalian Tianyu Pharmaceutical Co., Ltd.

• Founded in:

  1997-09-16

• Address:

  Houshi, Jinzhou District, Dalian City, Liaoning Province

• Tax NO.:

  91210213241831622W

• Registered Funds:

  7.01427 million yuan

• Website:

  Log in to view

• Email:

  Log in to view